Back to Directory
Enedra Therapeutics
East of England
Founded 2021
CASPAROV AI platform for targets in heterogeneous cancers
Enedra Therapeutics develops targeted cancer medicines designed to address genetic diversity within solid tumours, a major cause of treatment resistance.
Its CASPAROV platform combines cancer genomics, AI and functional biology to identify survival mechanisms shared across heterogeneous tumour cells. These convergent genomic signatures help identify drug targets and biomarkers for patient selection.
The Cambridge company is advancing three early-stage therapeutic programmes for molecularly stratified solid tumours.